North America HbA1c Testing Devices Market Revenue and Industry Share 2019

Some of the prominent players identified in the global market for hemoglobin A1c testing devices, based on the number of products, include Bio-Rad Laboratories, Inc., Tosoh Corporation, Siemens Healthcare, F. Hoffmann-La Roche Ltd, Alere, Inc., Chek Diagnostics, Danaher Corporation, and Trinity Biotech plc. These prominent players dominate the market for hemoglobin A1c testing devices with their exclusive products. 

For example, Bio-Rad Laboratories, Inc., offers devices based on ion-exchange HPLC and boronate affinity chromatography. Its ‘in2in’ point-of-care device is the latest addition with the automated boronate affinity chromatography technique. Additionally, Tososh Corporation offers many HbA1c testing devices based on ion-exchange HPLC technology whereas Siemens Healthcare presents two leading HbA1c testing products with immunoassay technology. According to a report by Transparency Market Research, the global hemoglobin A1c testing market is expected to reach US$1.8 bn by 2019.

Request For Discount On This Research Report:
http://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=1620

POC HbA1c Testing Devices Market Projected for Robust Growth

The global hemoglobin A1c testing devices market is segmented on the basis of end use and technology. Based on end use, this study includes laboratory and point-of-care (POC) testing devices. Laboratory testing devices continue to be the leading segment in the global market by end use and is projected to reach a valuation of US$1.1 bn by 2019. The POC HbA1c testing devices market, on the other hand, is expected to grow at a higher CAGR during the forecast period owing to the rising demand for these devices in developing economies such as India, Brazil, Africa, and others where access to laboratory testing is limited.

Geographically, North America holds the dominant share in the global market for hemoglobin A1c testing devices, owing to high patient awareness levels about HbA1c testing. This market share is, however, is expected to decline by 2019 with Asia Pacific gaining much traction by the end of the forecast period. The report notes that the market in the emerging economies of the Middle East, Africa, and Latin America is driven by factors such as the presence of high unmet healthcare needs, the high prevalence of diabetes, and increasing awareness about the various HbA1c testing technologies.

Exponentially Rising Cases of Diabetics Driving Demand

As per the International Diabetes Federation (IDF), the number of diabetics in the world is projected to reach 642 million by 2040, rising from 415 million in 2015. The report identifies this significant chunk of population as the primary driver in the market for hemoglobin A1c testing devices. Western Pacific and Southeast Asia are projected to have the most number of diabetics by 2035. Moreover, rising geriatric population is another factor that is driving the demand for hemoglobin A1c testing devices. People aged over 55 commonly suffer from diabetes and other endocrine diseases. Furthermore, the diabetes control and complications trial (DCCT) and United Kingdom prospective diabetes study (UKPDS) researches have established the fact that hemoglobin A1c testing on a regular basis improves the health outcome of a diabetes patient. This proven benefit is expected to encourage the market for the same during the forecast period. Conversely, the presence of viable and cost-efficient conventional blood glucose testing is hindering the awareness and concurrent adoption of hemoglobin A1c testing devices, globally.

According to the author of the report, “Emerging economies such as India, China, Philippines, Brazil, and other high growth countries in Asia Pacific, Africa, and the Middle East offer several untapped opportunities. These countries are investing heavily on improving their healthcare infrastructure. Also, the rapid commercialization of devices for diagnosis of diabetes is further fueling the market.”

Browse Research Report on Global Hemoglobin A1c Testing Devices Market:
http://www.transparencymarketresearch.com/hemoglobin-a1c-testing.html

Global Market for Hemoglobin A1c Testing Devices to Reach US$1.9 bn due to Rapid Commercialization of Home Testing Devices

Hemoglobin A1c is a hemoglobin test that primarily identifies the three-month average plasma glucose concentration. This test also helps in determining the type of diabetes and then gauge how well a person is managing diabetes. Hemoglobin A1c is also known by many other names, such as glycosylated hemoglobin, HbA1c, and glycated hemoglobin. The hemoglobin A1c test calculates the average of the blood sugar control over the previous 2 to 3 months and is used to make alterations in the dosage of diabetes medicines. Thus, most medical experts are recommending the use of these devices, which give precise results and help in monitoring blood sugar levels effectively, for diabetic patients.

Increasing Prevalence of Diabetes to Boost Sales of Hemoglobin A1c Testing Devices Worldwide

According to a research study by Transparency Market Research, in 2012, the global market for hemoglobin A1c testing devices was valued at US$0.9 bn and is estimated to reach a value of US$1.9 bn by the end of 2019. The market is projected to register a significant 10.30% CAGR between 2013 and 2019.

The tremendously rising number of diabetic patients, rising geriatric population, and proven benefits of hemoglobin A1c testing are some of the major factors that are expected to boost the demand for hemoglobin A1c testing devices globally in the next few years. In addition, the lucrative market opportunities in several developing nations and rapid commercialization of these devices for diagnosis of diabetes are some of the opportunities for the players operating in the global market for hemoglobin A1c testing devices.

On the flip side, the presence of viable substitutes and high costs of the test are the restraining factors that are projected to curb the growth of the market in the near future.

Point-of-care Testing Devices Segment to Register High Growth Rate between 2013 and 2019 

The global market for hemoglobin A1c testing devices can be classified on the basis of application into point-of-care testing devices and laboratory testing devices. In 2012, the laboratory testing devices segment dominated the market, accounting for a 66.2% share in the overall hemoglobin A1c testing devices market. This segment is estimated to remain in the leading position in the next few years; nevertheless, the point-of-care testing devices segment is also expected to witness a high growth rate in the same period.

Furthermore, on the basis of technology, the global market for hemoglobin A1c testing devices can be divided into:

• Ion-exchange HPLC
• Boronate Affinity Chromatography
• Immunoassay
• Direct Enzymatic Assay 
• Others (such as Micro-Optical Detection and Capillary Electrophoresis)

In 2012, the ion-exchange HPCL segment led the global market. However, the boronate affinity chromatography segment is anticipated to register the highest growth rate in the coming years.

Browse Research Release: 

http://www.transparencymarketresearch.com/pressrelease/global-hemoglobin-a1c-testing.htm

The increasing demand for hemoglobin devices has encouraged healthy competition among the major players operating in the market. Companies are spending a substantial amount on research and development activities to offer precise results for patients. Some of the major players in the global market for hemoglobin A1c testing devices are Sebia, Alere Inc., EKF Diagnostics Holdings plc, Chek Diagnostics, ARKRAY Inc., Menarini, Danaher Corp., Trinity Biotech, Siemens Healthcare, F. Hoffmann-La Roche Ltd., Bio-Rad Laboratories Inc., Tosoh Corp., and Abbott Laboratories.